MBI warns investors of unsought share bid

Article

Contrast agent developer Molecular Biosystems this month warned its shareholders of an unsought, below-market bid for up to 1% of MBI’s outstanding shares by a company called Towanda Partners ZG. MBI learned of the offer through shareholder queries.

Contrast agent developer Molecular Biosystems this month warned its shareholders of an unsought, below-market bid for up to 1% of MBI’s outstanding shares by a company called Towanda Partners ZG. MBI learned of the offer through shareholder queries. In an Aug. 12 statement, San Diego-based MBI emphasized that it did not endorse the $2.00 per share offer, as stockholders could get a higher price for their shares on the New York Stock Exchange, which on Aug. 11 posted a closing price per share of $2.25. Towanda Partners did not contact MBI before making its offer, which expired on Aug. 16.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.